White L, Reed C, Tobias V
Prince of Wales Children's Hospital, University of New South Wales, Australia.
Ophthalmic Paediatr Genet. 1989 Jun;10(2):99-105. doi: 10.3109/13816818909088349.
The benefits and optimal applications of chemotherapy in the management of retinoblastoma remain to be defined. There are major obstacles to its further study in the clinical setting. A xenograft model of human retinoblastoma heterotransplanted directly into the anterior chamber of the nude mouse eye has been adapted for evaluation of therapeutic efficacy. Cyclophosphamide, the most effective conventional drug, and diaziquone, an experimental agent, both produced documented and comparable responses in each of four xenograft cell lines. There was no evidence of rapidly emerging drug resistance or cross-resistance between two agents when sequential chemotherapy courses were given. Diaziquone is an effective chemotherapeutic agent for retinoblastoma in the xenograft model, and may have applications in clinical management.
化疗在视网膜母细胞瘤治疗中的益处和最佳应用仍有待确定。在临床环境中对其进行进一步研究存在重大障碍。一种将人视网膜母细胞瘤直接异种移植到裸鼠眼前房的异种移植模型已被用于评估治疗效果。环磷酰胺是最有效的传统药物，而重氮醌是一种实验性药物，两者在四种异种移植细胞系中均产生了有记录的且相当的反应。当给予序贯化疗疗程时，没有证据表明两种药物之间会迅速出现耐药性或交叉耐药性。重氮醌在异种移植模型中是一种有效的视网膜母细胞瘤化疗药物，可能在临床治疗中具有应用价值。
